KYTINUE Trademark

Trademark Overview


On Wednesday, September 27, 2023, a trademark application was filed for KYTINUE with the United States Patent and Trademark Office. The USPTO has given the KYTINUE trademark a serial number of 98199127. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, November 5, 2024. This trademark is owned by CSL Behring L.L.C.. The KYTINUE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of blood conditions; Pharmaceutical preparations for the treatment of transplant diseases, illnesses, and conditions; Pharmaceutical preparations for renal transplant diseases, illnesses, and conditions; Pharmaceutical preparations for kidney diseases, illnesses and conditions; Pharmaceutical preparations for treatment of antibody mediated rejection in adult renal transplant recipients; pharmaceutical preparations to treat hematology diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of emphysema diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions
kytinue

General Information


Serial Number98199127
Word MarkKYTINUE
Filing DateWednesday, September 27, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 2, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of blood conditions; Pharmaceutical preparations for the treatment of transplant diseases, illnesses, and conditions; Pharmaceutical preparations for renal transplant diseases, illnesses, and conditions; Pharmaceutical preparations for kidney diseases, illnesses and conditions; Pharmaceutical preparations for treatment of antibody mediated rejection in adult renal transplant recipients; pharmaceutical preparations to treat hematology diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of emphysema diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 11, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCSL Behring L.L.C.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressKing of Prussia, PA 19406

Party NameCSL Behring L.L.C.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressKing of Prussia, PA 19406

Trademark Events


Event DateEvent Description
Tuesday, February 20, 2024ASSIGNED TO EXAMINER
Saturday, September 30, 2023NEW APPLICATION ENTERED
Wednesday, October 11, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 26, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 13, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 2, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 2, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 4, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 5, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, November 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 5, 2024SOU EXTENSION 1 GRANTED
Tuesday, November 5, 2024SOU EXTENSION 1 FILED